Galactomannan of Delonix regia seeds reduces nociception and morphological damage in the rat model of osteoarthritis ind
- PDF / 1,358,207 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 49 Downloads / 156 Views
ORIGINAL ARTICLE
Galactomannan of Delonix regia seeds reduces nociception and morphological damage in the rat model of osteoarthritis induced by sodium monoiodoacetate Francisco Glerison da Silva Nascimento 1 & Pedro Henrique de Souza Ferreira Bringel 1 & Francisco Wildson Silva Maia 1 & Carlos Pinheiro Chagas Lima 2 & Rômulo Couto Alves 3 & Judith Pessoa Andrade Feitosa 2 & Mário Rogério Lima Mota 4 & Ana Maria Sampaio Assreuy 1 Rondinelle Ribeiro Castro 1
&
Received: 9 September 2020 / Accepted: 8 October 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract This study investigated the effects of the protein-free galactomannan obtained from Delonix regia seeds (GM-DR) in an experimental osteoarthritis (OA) model. GM-DR was obtained from water-homogenized endosperms by collection of the supernatant and precipitation with ethanol. The remaining proteins in the galactomannan were removed by alkaline hydrolysis. Weight average molar mass (Mw) of the galactomannan was estimated in 5.8 × 105 g mol−1, presenting mannose:galactose ratio of 2.39:1. Rats received sodium monoiodoacetate (OA groups, 1 mg/25 μL) or saline (sham group) in the right tibio-tarsal joint. GM-DR (30–300 μg) was administered by intra-articular route at days 14 and 21 after OA induction. Hypernociception was evaluated daily by the measurement of the mechanical threshold required to cause joint flexion and paw withdrawal reflex. The 56-day animal groups were euthanized for joint histopahological analysis using the OARSI score system. Lower doses of GMDR (30 and 100 μg) promoted antinociception from day 15 until the endpoint at day 56. Joint damage was reduced by GM-DR administration (100 μg) in OA-subjected animals, compared to the vehicle-treated OA group (5.9 ± 1.8 vs 19.0 ± 1.8, respectively, p < 0.05). Conclusion: Both antinociception and damage reduction suggest that Delonix regia galactomannan is a promising approach for osteoarthritis therapy. Keywords Galactomannan . Delonix regia . Sodium monoiodoacetete . Osteoarthritis . Hypernociception,·Inflammation
Introduction
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00210-020-01996-x) contains supplementary material, which is available to authorized users. * Rondinelle Ribeiro Castro [email protected] 1
Superior Institute of Biomedical Sciences, State University of Ceará, Av. Dr. Silas Munguba, 1700, Fortaleza, CE 60714-903, Brazil
2
Department of Organic and Inorganic Chemistry, Federal University of Ceará, Av. Mister Hull, s/n, Fortaleza, CE 60451-970, Brazil
3
Catarinian Federal Institute of Education, Science and Technology, R. Vigário Frei João, 550, Luzerna, SC 89609-000, Brazil
4
Department of Dental Clinic, Faculty of Pharmacy, Dentistry and Nursing, Federal University of Ceará, Street Alexandre Baraúna, 949, Fortaleza, CE 60430-160, Brazil
Osteoarthtitis (OA) is a prevalent human arthropathy, in which the current pharmacotherapy is mainly centered on the symptomatic relief, rather than to efficient
Data Loading...
